Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327249 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
A Phase 1 study of Multiple Myeloma, sponsored by AmpliMed Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00327249: Completed Phase 1 study of Multiple Myeloma, sponsored by AmpliMed Corporation.
NCT00327249 is a Phase 1 study of Multiple Myeloma that has completed, run by AmpliMed Corporation. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00327249, a Phase 1 study of Multiple Myeloma, has completed, sponsored by AmpliMed Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma
Conditions Studied
Interventions
- DRUG imexon
Study Locations (2)
Arkansas
- Investigational Site 025 - Little Rock
Texas
- Investigational Site 008 - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00327249 record still lists
NCT00327249 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which imexon is the first listed.
NCT00327249 reports a single indexed study location in Arkansas, Texas.
Frequently Asked Questions
What is clinical trial NCT00327249 about?
NCT00327249 is a clinical study titled "Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients". AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to ...
What is the current status of trial NCT00327249?
This trial is currently completed. It is a Phase 1 study. The study started on 2005-10. Estimated completion is 2008-01.
What conditions does trial NCT00327249 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00327249?
The interventions under investigation include: imexon (DRUG).
Who is sponsoring clinical trial NCT00327249?
This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00327249 being conducted?
This trial has 2 study locations across Arkansas, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia